MA28330A1 - Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine - Google Patents

Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine

Info

Publication number
MA28330A1
MA28330A1 MA29074A MA29074A MA28330A1 MA 28330 A1 MA28330 A1 MA 28330A1 MA 29074 A MA29074 A MA 29074A MA 29074 A MA29074 A MA 29074A MA 28330 A1 MA28330 A1 MA 28330A1
Authority
MA
Morocco
Prior art keywords
morpholine derivatives
norepinephrine
recapture inhibitors
inhibitors
norepinephrine recapture
Prior art date
Application number
MA29074A
Other languages
English (en)
Inventor
Gordon Iain Campbell
Manuel Javier Cases-Thomas
Teresa Man
John Joseph Masters
Helene Catherine Eugenie Rudyk
Magnus Wilhelm Walter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28330(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28330A1 publication Critical patent/MA28330A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

« DERIVES DE MORPHOLINE EN TANT QU'INHIBITEURS DE LA RECAPTAGE DE LA NOREPINEPHRINE » La présente invention concerne des composés représentés par la formule générale (I), qui sont des inhibiteurs du recaptage de la norépinéphrine. De ce fait, ils peuvent convenir pour le traitement de troubles du système nerveux central et/ou périphérique.
MA29074A 2003-11-10 2006-06-02 Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine MA28330A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326148.4A GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives
US53545904P 2004-01-09 2004-01-09

Publications (1)

Publication Number Publication Date
MA28330A1 true MA28330A1 (fr) 2006-12-01

Family

ID=29726235

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29074A MA28330A1 (fr) 2003-11-10 2006-06-02 Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine

Country Status (34)

Country Link
US (1) US7423037B2 (fr)
EP (2) EP1682523B1 (fr)
JP (1) JP4850068B2 (fr)
KR (1) KR100783855B1 (fr)
CN (1) CN1878762B (fr)
AR (1) AR046927A1 (fr)
AT (1) ATE478057T1 (fr)
AU (1) AU2004289616B2 (fr)
BR (1) BRPI0415273B8 (fr)
CA (1) CA2544649C (fr)
CR (1) CR8390A (fr)
CY (1) CY1110796T1 (fr)
DE (1) DE602004028750D1 (fr)
DK (1) DK1682523T3 (fr)
EA (1) EA009960B1 (fr)
EC (1) ECSP066555A (fr)
ES (1) ES2348872T3 (fr)
GB (1) GB0326148D0 (fr)
HK (1) HK1095135A1 (fr)
HR (1) HRP20100476T1 (fr)
IL (1) IL175365A (fr)
MA (1) MA28330A1 (fr)
MY (1) MY141048A (fr)
NO (1) NO336268B1 (fr)
NZ (1) NZ546067A (fr)
PE (1) PE20050491A1 (fr)
PL (1) PL1682523T3 (fr)
PT (1) PT1682523E (fr)
SI (1) SI1682523T1 (fr)
SV (1) SV2006001934A (fr)
TW (1) TWI339658B (fr)
UA (1) UA85198C2 (fr)
WO (1) WO2005047272A1 (fr)
ZA (1) ZA200603680B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399557T1 (de) * 2003-12-12 2008-07-15 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
RU2613633C1 (ru) * 2016-03-09 2017-03-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
NL108827C (fr) 1956-04-09
GB895309A (en) 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3141823A (en) 1962-09-04 1964-07-21 Res Lab Dr C Janssen N V Method for producing analgesia
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1999015177A1 (fr) 1997-09-23 1999-04-01 Eli Lilly And Company Traitement des troubles lies a l'hyperactivite et au deficit de l'attention
NZ520349A (en) * 1998-01-21 2004-02-27 Glaxo Group Ltd (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2- morpholinol and its salts and pharmaceuticals thereof
AU5889100A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DK1632234T3 (da) * 1999-07-01 2007-09-17 Pharmacia & Upjohn Co Llc (S,S)-reboxetin til behandling af kronisk træthedssyndrom
GB0120461D0 (en) * 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
FR2852954B1 (fr) * 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PE20050491A1 (es) 2005-08-24
CY1110796T1 (el) 2015-06-10
CR8390A (es) 2007-12-07
HK1095135A1 (en) 2007-04-27
CN1878762B (zh) 2010-10-27
SV2006001934A (es) 2006-02-15
WO2005047272A1 (fr) 2005-05-26
MY141048A (en) 2010-02-25
TW200524885A (en) 2005-08-01
EP1682523A1 (fr) 2006-07-26
CN1878762A (zh) 2006-12-13
PT1682523E (pt) 2010-09-20
PL1682523T3 (pl) 2011-01-31
ZA200603680B (en) 2007-07-25
NO20062700L (no) 2006-08-08
US20070083046A1 (en) 2007-04-12
HRP20100476T1 (hr) 2010-10-31
DK1682523T3 (da) 2010-11-15
JP4850068B2 (ja) 2012-01-11
AR046927A1 (es) 2006-01-04
KR20060086408A (ko) 2006-07-31
JP2007510720A (ja) 2007-04-26
IL175365A (en) 2011-02-28
KR100783855B1 (ko) 2007-12-10
BRPI0415273B8 (pt) 2021-05-25
DE602004028750D1 (de) 2010-09-30
ECSP066555A (es) 2006-10-17
GB0326148D0 (en) 2003-12-17
US7423037B2 (en) 2008-09-09
TWI339658B (en) 2011-04-01
AU2004289616A1 (en) 2005-05-26
NZ546067A (en) 2009-04-30
AU2004289616B2 (en) 2010-08-05
EP2223916A1 (fr) 2010-09-01
IL175365A0 (en) 2006-09-05
BRPI0415273B1 (pt) 2019-04-30
BRPI0415273A (pt) 2006-12-19
EA200600945A1 (ru) 2006-10-27
EP1682523B1 (fr) 2010-08-18
EA009960B1 (ru) 2008-04-28
CA2544649A1 (fr) 2005-05-26
CA2544649C (fr) 2012-08-14
SI1682523T1 (sl) 2010-12-31
ES2348872T3 (es) 2010-12-16
ATE478057T1 (de) 2010-09-15
NO336268B1 (no) 2015-07-06
UA85198C2 (ru) 2009-01-12

Similar Documents

Publication Publication Date Title
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
EA200700909A1 (ru) Азаиндолкарбоксамиды
TNSN06300A1 (fr) Derives d'imidazole pour le traitement de troubles neurodegeneratifs
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
MA35836B1 (fr) 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
MA30412B1 (fr) Composés Pharmaceutiques
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
TNSN06314A1 (fr) Sulfonamides destines au traitement de troubles neurodegeneratifs
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
TNSN05309A1 (fr) Derives d'imidazole utilises comme antagonistes du recepteur du glutamate
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DK1456380T3 (da) SMAD7-inhibitorer til behandling af CNS-sygdomme
MA32506B1 (fr) Nouveaux composes
MA50398B1 (fr) Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma